Given the crucial role of the adenosinergic pathway in tumor progression, strategies that block CD39, CD73, and/or A2AR may offer dual benefits, limiting tumor progression while restoring anti‐tumor immunity.[62, 63, 64, 65] Several agents targeting these molecules are currently under clinical investigation.[12, 26] For instance, the A2A receptor antagonist (SCH) combined with anti‐PD‐1 has shown a substantial reduction in both experimental and spontaneous metastases and has prolonged mouse survival compared to monotherapy.[64]. The gene discussed is ENTPD1; the disease is neoplasm.